Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering

Journal of Lipids
Dhrubajyoti BandyopadhyayRaktim K Ghosh

Abstract

PCSK9 inhibitors, monoclonal antibodies, are novel antihypercholesterolemic drugs. FDA first approved them in July 2015. PCSK9 protein (692-amino acids) was discovered in 2003. It plays a major role in LDL receptor degradation and is a prominent modulator in low-density lipoprotein cholesterol (LDL-C) metabolism. PCSK9 inhibitors are monoclonal antibodies that target PCSK9 protein in liver and inhibiting this protein leads to drastically lowering harmful LDL-C level in the bloodstream. Despite widespread use of the statin, not all the high-risk patients were able to achieve targeted level of LDL-C. Using PCSK9 inhibitors could lead to a substantial decrement in LDL-C plasma level ranging from 50% to 70%, either as a monotherapy or on top of statins. A large number of trials have shown robust reduction of LDL-C plasma level with the use of PCSK9 inhibitors as a monotherapy or in combination with statins in familial and nonfamilial forms of hypercholesterolemia. Moreover, PCSK9 inhibitors do not appear to increase the risk of hepatic and muscle-related side effects. PCSK9 inhibitors proved to be a highly potent and promising antihypercholesterolemic drug by decreasing LDL-R lysosomal degradation by PCSK9 protein. Statin drugs are...Continue Reading

References

May 16, 2002·Neurology·D GaistS H Sindrup
May 6, 2003·Nature Genetics·Marianne AbifadelCatherine Boileau
Dec 2, 2004·JAMA : the Journal of the American Medical Association·David J GrahamRichard Platt
May 25, 2005·Circulation·Alawi A Alsheikh-AliRichard H Karas
Mar 14, 2007·Journal of Molecular Medicine : Official Organ of the Gesellschaft Deutscher Naturforscher Und Ärzte·Nabil G Seidah, Annik Prat
Sep 18, 2007·Current Opinion in Structural Biology·Stephen C Blacklow
Oct 24, 2007·The American Journal of Cardiology·Joanna M YoungRussell S Scott
Jul 22, 2008·Biochemical and Biophysical Research Communications·Kenneth R FeingoldCarl Grunfeld
Sep 24, 2008·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Donald A RedelmeierNick Daneman
Dec 15, 2010·The Journal of Biological Chemistry·Taichi YamamotoRobert O Ryan
Jan 21, 2011·The American Journal of Cardiology·Dean G KaralisMark F Victor
Feb 19, 2013·European Heart Journal·G Kees HovinghAnne M O'Connor
Aug 27, 2013·Journal of the American College of Cardiology·Daniel UrbanUlrich Laufs
Dec 20, 2013·Circulation·Alan S GoUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Mar 15, 2014·Circulation Research·Nabil G SeidahMajambu Mbikay
Apr 1, 2014·The New England Journal of Medicine·Dirk J BlomUNKNOWN DESCARTES Investigators
Apr 3, 2014·Journal of the American College of Cardiology·Michael J KorenUNKNOWN MENDEL-2 Investigators
Jun 14, 2014·Vascular Pharmacology·Giuseppe Danilo NorataAlberico Luigi Catapano
Aug 21, 2014·Journal of Lipid Research·Susan KühnastHans M G Princen
Oct 17, 2014·Science Translational Medicine·Keith R WalleyJohn H Boyd
Dec 4, 2014·Nutrients·Ioanna Gouni-Berthold, Heiner K Berthold
Jan 1, 2014·Global Cardiology Science & Practice·Mohamed Hassan, Magdi Yacoub
Apr 1, 2015·Circulation·David H FitchettSubodh Verma
Apr 19, 2015·Current Opinion in Lipidology·Bertrand CariouCédric Le May
Apr 25, 2015·Expert Opinion on Drug Safety·Maciej BanachDimitri P Mikhailidis
May 21, 2015·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Kristopher J Swiger, Seth S Martin
Jun 21, 2015·Cardiovascular Research·Zufeng DingJawahar L Mehta
Jun 26, 2015·Drug Design, Development and Therapy·Arrigo F G CiceroClaudio Borghi
Jul 3, 2015·Vascular Pharmacology·Harry C BlairDionysios J Papachristou
Nov 18, 2015·Deutsches Ärzteblatt International·Ulrich LaufsWinfried März

❮ Previous
Next ❯

Citations

Jul 10, 2019·Scientific Reports·Mario FailliVittorio Fortino
Jun 9, 2020·Expert Opinion on Pharmacotherapy·Paramarjan Piranavan, Andras Perl
Jun 15, 2018·Nutrients·Milessa Silva AfonsoAna Maria Lottenberg
Jul 11, 2019·European Journal of Preventive Cardiology·Fabrizio MontecuccoAmirhossein Sahebkar
Dec 29, 2020·Neurología : publicación oficial de la Sociedad Española de Neurología·A Gil-NúñezE Palacio
Dec 19, 2020·Clinical Pharmacology : Advances and Applications·Constantine E KosmasEliscer Guzman
Mar 24, 2021·Journal of Cardiac Failure·Yasser SammourBrett W Sperry

❮ Previous
Next ❯

Methods Mentioned

BETA
antisense oligonucleotide

Clinical Trials Mentioned

NCT01592240

Software Mentioned

GLAGOV
DESCARTES
MENDEL
OSLER

Related Concepts

Related Feeds

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Related Papers

Türk Kardiyoloji Derneği arşivi : Türk Kardiyoloji Derneğinin yayın organıdır
Ahmet AvciBülent Behlül Altunkeser
Current Cardiology Reports
Peta King, Stephen J Nicholls
Journal of Atherosclerosis and Thrombosis
Tsuyoshi Nozue
© 2022 Meta ULC. All rights reserved